Abstract:IntroductionThe study of the pathophysiology study of Alzheimer’s disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration.MethodsThe humanized APPNL-G-F knock-in mouse line was crossed to the PS19 MAPTP301S, over-expression mouse line to create the dual APPNL-G-F/PS19 MAPTP301S line. The resulting pathologies were characterized by immunochemical methods and PCR.ResultsWe now report on a double transgenic APPNL-G-F/PS19 MAPTP301S mouse that at 6 months of age exhibits robust A plaque accumulation, intense MAPT pathology, strong inflammation and extensive neurodegeneration. The presence of A pathology potentiated the other major pathologies, including MAPT pathology, inflammation and neurodegeneration. MAPT pathology neither changed levels of amyloid precursor protein nor potentiated A accumulation. Interestingly, study of immunofluorescence in cleared brains indicates that microglial inflammation was generally stronger in the hippocampus, dentate gyrus and entorhinal cortex, which are regions with predominant MAPT pathology. The APPNL-G-F/MAPTP301S mouse model also showed strong accumulation of N6-methyladenosine (m6A), which was recently shown to be elevated in the AD brain. m6A primarily accumulated in neuronal soma, but also co-localized with a subset of astrocytes and microglia. The accumulation of m6A corresponded with increases in METTL3 and decreases in ALKBH5, which are enzymes that add or remove m6A from mRNA, respectively.DiscussionOur understanding of the pathophysiology of Alzheimer’s disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. The APPNL-G-F/MAPTP301S mouse recapitulates many features of AD pathology beginning at 6 months of aging, and thus represents a useful new mouse model for the field.

Advance on Research of Alzheimer Disease Transgenic Mice Model

Characteristics and Application of Transgenic Mouse Models in Alzheimer's Disease

Current Status of Genetic Engineering Mouse Models of Alzheimer's Disease

Critical thinking of Alzheimer's transgenic mouse model: current research and future perspective

Mouse Models of Alzheimer’s Disease

APP mouse models for Alzheimer's disease preclinical studies

Updates on mouse models of Alzheimer's disease

Insights on the Use of Transgenic Mice Models in Alzheimer's Disease Research

Updates on Mouse Models of Alzheimer’s Disease

Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer's disease

[The Comparative Study on High Field MRI and Pathology of Alzheimer's Disease Transgenic Mice].

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease

Establishment and Evaluation of Transgenic Models of Alzheimer's Disease with Senescence Accelerated Background

Pathophysiologic abnormalities in transgenic mice carrying the Alzheimer disease PSEN1 Δ440 mutation

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

Alzheimer’s disease: experimental models and reality

Modeling Alzheimer'S Disease In Mouse Without Mutant Protein Overexpression: Cooperative And Independent Effects Of A Beta And Tau

Lack of Human-Like Extracellular Sortilin Neuropathology in Transgenic Alzheimer’s Disease Model Mice and Macaques

Animal Models of Alzheimer's Disease: Current Strategies and New Directions.

Practical considerations for choosing a mouse model of Alzheimer’s disease